While a previous effort to force the disclosure of net drug prices was scuttled amid legal challenges, President Donald Trump recently made it clear that he hopes to revisit the issue amid a renewed push for health care price transparency.
PBMs Must Prepare For Revival Of Drug Price Transparency Requirements
Experts say PBMs should become familiar with transparency rules and prepare to release data, although more legal wrangling could occur.
More from PBMs
• By
Experts say PBMs should become familiar with transparency rules and prepare to release data, although more legal wrangling could occur.
• By
Optum Rx, one of the largest PBMs in the US, declared it was the “first comprehensive, transparent pharmacy services company” after announcing several consumer-friendly changes.
• By
An analysis of Medicare Part D and other data found that more than one-third of all pharmacy spending went through pharmacies owned by Cigna, CVS Health, Humana or UnitedHealth Group.
• By
The leader of the House Energy and Commerce Health Subcommittee has a plan for passing pharmacy benefit manager reforms, but Democrats are skeptical.
More from Market Access
• By
England’s health technology assessment institute, NICE, is looking to “reimagine” its evaluation process with the help of AI, rather than just using this technology to speed up its existing processes.
• By
Calley Means defended reductions in force at the Health and Human Services Department that shocked and outraged federal workers and stakeholders.
• By
CMED, which sets medicine prices in Brazil, has published the maximum price adjustment index for 2025.